|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of SGLT2 inhibitor administration on exercise endurance and skeletal muscle mitochondrial function with fatty acid oxidation in a murine model of HF after the induction of myocardial infarction (MI).
|
31738936 |
2020 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.<sup>1</sup> Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).<sup>2-3</sup> Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.<sup>1</sup> We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%.
|
31707795 |
2020 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hazard ratios for secondary outcomes, comparing SGLT2 inhibitors with DPP4 inhibitors, were 0.99 (0.85 to 1.17) for myocardial infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 to 1.08) for cardiovascular death, and 0.80 (0.69 to 0.92) for any cause death.
|
31467044 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we examined the effects of an SGLT2 inhibitor on the acute survival rate after myocardial infarction (MI) in an animal model of type 2 diabetes mellitus (DM) and the possible involvement of modification of cardiac metabolomes and antioxidative proteins.
|
30552292 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the effect of SGLT2 inhibition with empagliflozin (EMPA) on cardiac function in non-diabetic rats with left ventricular (LV) dysfunction after myocardial infarction (MI).
|
31033127 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with the control, SGLT2 inhibitor treatment was associated with a reduction in the incidence of major adverse cardiovascular events (MACEs) (OR = 0.86, 95% CI 0.80-0.93, P < .0001), myocardial infarction (OR = 0.86, 95% CI 0.79-0.94, P = .001), cardiovascular mortality (OR = 0.74, 95% CI 0.67-0.81, P < .0001) and all cause mortality (OR = 0.85, 95% CI 0.79-0.92, P < .0001).
|
31804352 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three randomized control trials (Canagliflozin Cardiovascular Assessment Study, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME], and Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 [DECLARE-TIMI 58]) showed that the sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering drugs, are associated with a lower rate of adverse renal outcomes, such as need for renal replacement therapy, doubling of serum creatinine, and loss of glomerular filtration rate (GFR) compared to those in placebo groups.
|
30939483 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
|
29569378 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meta-analyses showed that SGLT2 inhibitors significantly reduced the risks of major adverse cardiac events (hazard ratio [HR]: 0.80; 95% confidence interval [CI], 0.69-0.92; <i>P</i>=0.002), all-cause mortality (HR: 0.67; 95% CI, 0.54-0.84; <i>P</i><0.001), cardiovascular mortality (HR: 0.77; 95% CI, 0.60-0.98; <i>P</i>=0.03), nonfatal myocardial infarction (HR: 0.86; 95% CI, 0.76-0.98; <i>P</i>=0.02), hospitalization for heart failure (HR: 0.62; 95% CI, 0.55-0.69; <i>P</i><0.001), and progression of albuminuria (HR: 0.68; 95% CI, 0.58-0.81; <i>P</i><0.001).
|
29353233 |
2018 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pooled results show that SGLT2 inhibitors, when compared to placebo, significantly reduce all-cause mortality (OR 0.79, 95% CI 0.70-0.89; P < 0.001), major adverse cardiac events (OR 0.8, 95% CI 0.76-0.92; P < 0.001), non-fatal myocardial infarction (OR 0.85, 95% CI 0.73-0.98; P = 0.03) and heart failure/hospitalisation for heart failure (OR 0.67, 95% CI 0.59-0.76; P < 0.001) in patients with type 2 diabetes mellitus.
|
29372664 |
2018 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction.
|
30291295 |
2018 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT-2 inhibitors were significantly associated with lower rates of HF events (absolute RD, -1.1%; HR, 0.62 [95% CrI, 0.54 to 0.72]) and MI (absolute RD, -0.6%; HR, 0.86 [95% CrI, 0.77 to 0.97]) than were the control groups.
|
29677303 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relative risks of MI with SGLT2 inhibitor use were 0.77 (0.63-0.93) and 0.75 (0.60-0.94), compared with placebo and DPP4 inhibitor, respectively.
|
28542373 |
2017 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with placebo, SGLT-2 inhibitors were associated with a lower risk of all-cause mortality (OR 0.72; 95% CI 0.59-0.86; P<0.001), cardiovascular mortality (OR 0.67; 95% CI 0.53-0.84; P=0.001), and heart failure (OR 0.67; 95% CI 0.51-0.87; P=0.003), but a similar risk of myocardial infarction (OR 0.89; 95% CI 0.74-1.09; P=0.29) and stroke/transient ischemic attack (OR 1.09; 95% CI 0.87-1.37; P=0.47).
|
27866027 |
2017 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
We did not identify significant differences between use of SGLT2 inhibitors and use of other glucose-lowering drugs for non-fatal myocardial infarction, non-fatal stroke, or atrial fibrillation.
|
28781064 |
2017 |